The Role of Nuclear Receptor PPAR in Liver Fibrosis

肝纤维化是反复肝损伤和炎症导致肝脏形成纤维瘢痕，主要由非酒精性脂肪肝病(NAFLD)及非酒精性脂肪性肝炎(NASH)、慢性毒性损伤、代谢相关损伤等引起，可导致肝衰竭、肝硬化等，甚至可能会导致肝癌。目前，临床上对肝纤维化的发病机制和治疗进行了许多研究，并取得了一些进展。其中，临床前研究表明，过氧化物酶体增殖物激活受体(PPAR)参与炎症、能量平衡、脂质代谢、葡萄糖稳态的转录调节，在防治肝纤维化的发展中起到十分重要的作用。在本文中我们概述过氧化物酶体增殖物激活受体在肝纤维化中发展中的机制，并讨论以过氧化物酶体增殖物激活受体为靶点的抗纤维化药物的发展潜力。Liver fibrosis is the formation of fibrotic scars in the liver due to repeated liver injury and inflammation, mainly caused by non-alcoholic fatty liver disease (NAFLD) and non-alcoholic fatty hepatitis (NASH), chronic toxic injury, metabolic related injury, etc. It can lead to liver failure, cirrhosis, and even liver cancer. At present, there have been many studies on the pathogenesis and treatment of liver fibrosis in clinical practice, and some progress has been made. Among them, preclinical studies have shown that peroxisome proliferator activated receptor (PPAR) is involved in transcriptional regulation of inflammation, energy balance, lipid metabolism, and glucose homeostasis, and plays a crucial role in preventing and treating the development of liver fibrosis. In this article, we outline the mechanisms underlying the development of peroxisome proliferator activated receptors in liver fibrosis and discuss the potential for the development of anti fibrotic drugs targeting peroxisome proliferator activated receptors.